Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

RCTbaricitinibplaceboCOVID 19 hospitalizedlow
764/761 suggested -39% 23%
ACTT-2 (Kalil)
RCTbaricitinibplaceboCOVID 19 hospitalizedlow
515/518 conclusif -32% demonstrated14% -28%

COVID 19 all comers meta-analysis

RCTbaricitinibstandard of careCOVID 19 all comerssome concern
4148/4008 conclusif demonstrated-12% -9%

COVID-19 severe or critically meta-analysis

COV-BARRIER (critically ill)
RCTbaricitinibplaceboCOVID-19 severe or criticallylow
51/50 suggested -41% 168%
3 studies excluded by filtering options (0 RCT / 3 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).